CD 270 | 104224-10-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: CD 270
• 英文别名: 2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-6-benzo(b)-thiophene carboxylic acid；2-(5,5,8,8-Tetramethyl-6,7-dihydronaphthalen-2-yl)-1-benzothiophene-6-carboxylic acid
• CAS: 104224-10-4
• 化学式: C₂₃H₂₄O₂S
• 分子量: 364.508
• InChiKey: VYBLDUKQAWIMMM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  methyl 2-(5,6,7,8-tetrahydro-5,5-8,8-tetramethyl-2-naphthyl)-6-benzo(b)thiophene carboxylate 生成 CD 270
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis
  申请人：——

  公开号：US20030092758A1

  公开（公告）日：2003-05-15

  The present invention relates to the use of at least one RAR receptor agonist ligand, particularly 6-[3-(adamantan-1-yl)-4-(prop-2-ynyloxy)phenyl]naphthalene-2-carboxylic acid or 5-[(E)-3-oxo-3-(5,5,8,8-tetrahydronaphthalene-2-yl)propenyl]thiophene-2-carboxylic acid, to prepare a pharmaceutical composition for increasing the rate of apoptosis in at least one cell population in which apoptosis may be induced by activating RAR-&ggr; receptors. The composition is particularly useful for treating a disease or disorder related to an insufficient rate of apoptosis in at least one cell population in which apoptosis may be induced by activating RAR-&ggr; receptors. The invention further relates to the use of at least one RAR receptor agonist ligand, particularly 6-[3-(adamantan-1-yl)-4-(prop-2-ynyloxy)phenyl]naphthalene-2-carboxylic acid or 5-[(E)-3-oxo-3-(5,5,8,8-tetrahydronaphthalene-2-yl)propenyl]thiophene-2-carboxylic acid, as the active ingredient in a pharmaceutical or cosmetic composition and the use of such RAR agonist ligands to treat various disorders associated with apoptosis, differentiation, and proliferation. The compositions of the present invention may be used to prevent and/or control photo-induced or chronological aging of the skin.

  本发明涉及使用至少一种RAR受体激动剂配体，特别是6-[3-(孔雀石-1-基)-4-(丙-2-炔氧基)苯基]萘-2-羧酸或5-[(E)-3-氧代-3-(5,5,8,8-四氢萘-2-基)丙烯基]噻吩-2-羧酸，用于制备一种药物组合物，以增加至少一种细胞群体中凋亡速率，其中通过激活RAR-γ受体可以诱导凋亡。该组合物特别适用于治疗与至少一种细胞群体中凋亡速率不足相关的疾病或紊乱，其中通过激活RAR-γ受体可以诱导凋亡。该发明还涉及使用至少一种RAR受体激动剂配体，特别是6-[3-(孔雀石-1-基)-4-(丙-2-炔氧基)苯基]萘-2-羧酸或5-[(E)-3-氧代-3-(5,5,8,8-四氢萘-2-基)丙烯基]噻吩-2-羧酸，作为药用或化妆品组合物中的活性成分，以及使用这些RAR激动剂配体治疗与凋亡、分化和增殖相关的各种紊乱。本发明的组合物可用于预防和/或控制皮肤的光致老化或年代老化。
• Use of retinoids for preventing and reducing the size of striae distensae lesions
  申请人：Kligman, Albert M.

  公开号：EP0415458A2

  公开（公告）日：1991-03-06

  Striae distensae lesions may be prevented and/or reduced in size by topically applying to the skin affected with the lesions an effective amount of a retinoid, preferably retinoic acid, preferably by daily application in a dermatologically acceptable vehicle, such as a cream base, at a concentration of about 0.025 to 0.1 weight percent retinoic acid. When applied during the striae rubrae stage, the retinoid may be effective to prevent the formation of striae albae lesions, and when applied in either stage, the retinoid may be effective to reduce the width and depth of the lesions, with improved texture and softness.

  可通过在受皮损影响的皮肤上局部施用有效量的维甲酸（最好是维甲酸）来防止和/或缩小红斑皮损，维甲酸的浓度最好为 0.025 至 0.1 重量百分比。在红斑期施用时，维甲酸可有效防止白斑的形成；在任何一个阶段施用时，维甲酸可有效减少皮损的宽度和深度，并改善质地和柔软度。
• Methods of treating proteinuria
  申请人：Vaughan R. Michael

  公开号：US20050112123A1

  公开（公告）日：2005-05-26

  The present invention provides methods of treating proteinuria, and treating renal disorders associated with proteinuria, the methods generally involving administering to an individual having such a disorder an effective amount of retinoic acid receptor agonist or a retinoid X receptor agonist.

  本发明提供了治疗蛋白尿和与蛋白尿相关的肾脏疾病的方法，这些方法一般涉及向患有此类疾病的个体施用有效量的维甲酸受体激动剂或维A酸X受体激动剂。
• ——
  作者：SHROOT B.、 EUSTACHE J.、 BERNARDON J. -M.

  DOI：——

  日期：——
• Composition pharmaceutique ou cosmétique contenant en association un rétinoîde et un stérol
  申请人：CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA

  公开号：EP0465343B1

  公开（公告）日：1994-06-15